IMS Health RWES: The Future of Real-World Insights in Cancer

1. REAL-WORLD EVIDENCE SOLUTIONS
An RWE ecosystem for commercial and clinical success
MEET THE
FUTURE OF
REAL-WORLD
INSIGHTS IN
CANCER

2. 2
CHALLENGES
Cancer and its Complexity
Discovering and assessing cancer therapies demands the
best insights into disease etiology, treatment, impact, and
outcomes. Robust analyses must account for the specific
interests of all stakeholders and a variety of issues across
the spectrum of cancers.
• Clinicians facing highly sophisticated
treatment decisions and patient
stratification
• Payers wanting more proof of value as
innovations challenge stretched budgets
• Pharma generating more innovative
evidence
• Patients and caregivers impacting
therapeutic options
• Increasing role of advocacy groups in
awareness building and data generation

3. 3www.imshealth.com/rwe
HOLISTIC APPROACH
IMS RWE Cancer Ecosystem
Creating a common
foundation of the right
oncology real-world data
(RWD) to address the
cancer-related needs of
your entire organization
IMS Health combines anonymous patient data with
advanced analytics, powerful processing, and deep
scientific and commercial expertise to deliver credible,
breakthrough oncology insights.

4. 4
IMS RWE CANCER ECOSYSTEM
Multi-source data representing
macro-to-patient-level RWD
Comprehensive,
Global Cancer Data
Innovative and client-centric
technology solutions
Technology-Enabled
Analytics
Delivered by a global,
dedicated team, including
tumor-specific specialists
Expertise-Driven
Oncology Services
Unparalleled
Oncology
Capabilities

5. 5www.imshealth.com/rwe
• Comprehensive cross-sectional
survey data
- Coverage of 25+ primary cancers
across 15+ markets
- 200,000+ patient histories per year
from 4,000+ specialists
• IMS MIDAS sales data integration
• Primary data collection from specialists
and patients
• Promotional data
• More than 10 years of data from
15+ million anonymous cancer patients
- EMR data
- Medical claims data
- Hospital data
- Prescription data
- Consumer data
- Biomarker and genomic
alteration data
• Largest, most comprehensive
cancer platform commercially
available in the USA
• EMR extraction capabilities in Europe
• Predictive analytics algorithms
• Intelligent data interfaces and
visualization
• Data-linking technologies designed
to protect privacy
• Disease, patient, and therapy
understanding
• RD targeting and efficiency
• Market access strategies
• Real-world value demonstration,
including HEOR, pharmacoepidemiology,
and drug safety
• Commercial positioning, planning,
and performance tracking

6. 6
UNIQUE APPROACH TO DATA
Partnering for Richer Data to
Support Precision Therapy
• Granular understanding of the
comprehensive patient pathway
• Insights into differences in unmet
needs, treatment use, cost,
and outcomes among different
genomic subpopulations
• Evaluation of targeted therapies,
based on unique molecular
drivers of individual cancers
The IMS Health and Foundation Medicine collaboration
enables unique linkage of biomarker data with other
sources of RWD such as payer claims and oncology
EMR at an anonymous patient level. This provides an
unprecedented evidence base for improved
medical-scientific and commercialization strategies.
Biomarker Duration of Therapy
Median Days on Erlotinib Therapy (linked cohort n=152)
Source: IMS Health retrospective analysis of IMS RWD Pharmacy Prescription and Medical Claims
linked to Foundation Medicine molecular profiling data
107
365
115
312
135
358
EGFR- EGFR+ EGFR+
Exon
20 mut
EGFR+
non-Exon
20 mut
KRAS+ KRAS-

7. 7www.imshealth.com/rwe
CUSTOM RWD SOLUTIONS
Sourcing and Linking Expertise for
T-Shaped Evidence Networks
Strategic Data Sourcing
• Enhance existing RWD through custom
sourcing support to extract data and
create custom datasets
• Identify and access new data sources
addressing specific research needs,
also in niche markets
• Benefit from IMS RWD Catalogue of
2,200+ data sources globally, including
40%+ in oncology
Data Linkage
• Understand the full patient pathway
through integrating datasets at the
record level (e.g., USA and Scandinavia)
• Gain deeper insights by sales indication
through integration with IMS MIDAS
sales data
T-Shaped Evidence Networks
Broad
Deep
RangeofDataTypes
Population Coverage
Nationally relevant databases
Augmented datasets
Biobank, labs, registries
IMS Health T-shaped Evidence Networks
address the need to consider both breadth
and depth of RWD when accessing the most
appropriate fact base

8. 8
IMS Health has established excellence in global and local
cancer-related research in mature and emerging markets.
Proven Approach: We have a track record of successful HTA
submissions, published findings, and EMA-accepted Drug Utilization
Studies in multiple therapy areas and geographies. Our bibliography
comprises more than 3,500 publications, with 520+ in solid and
liquid tumors.
Quality Systems: Our leading Quality Management System
includes electronic control of standards, audit trail, and computer
system validation.
Credible Solutions: Our databases and methods have been
validated in peer-reviewed publications and are used by academics
and authorities. They serve as part of a framework for safety
assessment and for regulatory purposes.
OUR SCIENTIFIC COMMITMENT
Bringing Scientific Credibility
and Quality to All Our Work

9. 9www.imshealth.com/rwe
SERVICES
Helping Stakeholders
All functions can derive value through a shared view
of what is happening in real-life healthcare settings.
• Launch pricing support
• Tumor-specific forecasting
• Ongoing value differentiation
• Launch/promotion planning
• Segmentation and targeting
• Cancer patient journeys
Commercial
• Drug utilization/monitoring
• Rigorous and efficient tumor modeling
• EMR-enabled outcomes research
• Local burden of illness/disease
• Adverse event/signal detection
• Regulatory submissions and responses
HEOR,
Pharmacoepidemiology,
and Drug Safety
• Custom data sourcing
• E360TM
technology suite
• Evidence platforms
• T-shaped Cancer Evidence Networks
RWE Platform
Developers
• Translational research
• Drug pathways
• Target population/product profile
• Trial and recruitment feasibility
RD

10. 10
EVIDENCE PLATFORM
IMS RWD Oncology US Platform
• More than 10 years
of data from 15+ million
anonymous cancer
patients
Our comprehensive cancer data platform links multiple data
types, including EMRs, across settings of care.
RD
Predictive
Analytics Tools
Medical-Scientific
Studies/
Publications
HEOR
Forecasting
KOL Engagement
Commercial
Patient
Analytics
Software Application
(e.g., E360TM
, SAS, R, Tableau)
Platform
Core
Deep
Clinical Data
(e.g., Genomics
Data)
Enriched Data
(e.g., NLP,
Linkage, Local
Registry)
Broad, Nationally Relevant Databases (e.g., IMS RWD Claims Data)
Augmented Datasets (e.g., Oncology EMR)
• Data Integration
• Data Hosting
• Business Rules Analytical Methods
• Ongoing Data Governance
T-Shaped Portfolio
of Data Sources
Services
Engagement
Technology-
Enabled Analytics
Real-World
Data
• Geographically
representative of
the USA to enable
a projectable base
• Integrates biomarker,
histology, consumer,
and other patient
datasets

11. 11www.imshealth.com/rwe
HOW WE HELP
Enhancing RCT Results with RWE
OUR CHALLENGE
Help our client determine whether the
rate and timing of hemoglobin (Hb)
decline in cancer patients receiving
chemotherapy seen in pooled RCT
was representative of the real world.
OUR RESULTS
Our analysis verified the RCT findings, increasing payer confidence in those
clinical results. This approach can help support future launch strategies when
there is uncertainty regarding the applicability of RCT results to real-life settings.
OUR SOLUTION
We analyzed pooled data from six
RCTs and replicated the analysis
using our US community oncology
clinic EMR database.
440
Patients
5,922
Additional patient
experiences analyzed

12. IMS Health Real-World Evidence Solutions
Uncovering insights from real-world data to improve decision making and patient outcomes
©2016 IMS Health Incorporated and its affiliates. All rights reserved.
IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated.
IMS RWD
Oncology Dynamics
The latest addition to the IMS Health
cross-sectional survey portfolio
CONTACT US FOR
MORE INFORMATION
The Americas
One IMS Drive
Plymouth Meeting, PA 19462
USA
Tel: +1 484 567 6461
Europe
210 Pentonville Road
London, N1 9JY
United Kingdom
Tel: +44 (0) 20 3075 4800
rweinfo@imshealth.com
www.imshealth.com/rwe
www.linkedin.com/company/
ims-health-real-world-evidence
www.twitter.com/IMSHealthRWE
• New global study
covering all key tumor
types, stages, and lines
of therapy
• Large physician panel
with high patient
sample sizes
• Facilitates
understanding of
cancer treatment
paradigms
• Modern, web-based
analytical tool to gain
immediate insights
NEWIN 2016!
IMS HEALTH
REAL-WORLD
EVIDENCE
SOLUTIONS
ALK Status
Key Cancer: Patient Count NSCLC: Line of Therapy
1st
2nd
Awaiting
Results
Wild
Mutant
0 100 200 300
NSCLC
COLORECTAL
BREAST
ALL OTHERS
PROSTATE
NHL
PANCREAS
KIDNEY
OVARIAN
CLL
BLADDER
CML
STOMACH
SCLC
AML
MELANOMA
KEY CANCER
Count (Patient-ID)
Not
Tested
NSCLC
3rd+
Patient Profile
IMS RWD Oncology Dynamics
https://websolutions.imshealth.com/EB2/User/CustomerLogin